Inclusion Criteria:

          -  RCC (clear cell), urothelial carcinoma (UC) (transitional cell), gastric or
             gastro-esophageal junctional (GEJ) adenocarcinoma, or K-RAS or N-RAS wild-type EGFR
             expressing CRC

          -  For cohort 1 RCC: minimum of 1 and maximum of 4 prior regimens, one or more of which
             must have included a VEGF-TKI

          -  For UC cohort 2: minimum of 1 and maximum of 2 prior regimens, one of which must have
             included a platinum-based regimen

          -  For UC cohort 5: Minimum of 1 and maximum of 2 prior regimens, one of which must have
             included a checkpoint inhibitor.

          -  For UC cohort 6:

               -  Locally advanced or mUC who are not eligible for cisplatin chemo with a PDL-1
                  score (CPS) of ≥ 10 without prior treatment.

               -  Locally advanced or mUC who have progressed on platinum chemo or within 12 months
                  of neo- or adjuvant therapy with a platinum chemotherapy. A minimum of 1 and
                  maximum of 2 prior therapies.

          -  For cohort 3 gastric or GEJ adenocarcinoma: minimum of 1 and maximum of 3 prior
             regimens one of which must have included a fluoropyrimidine regimen

          -  For cohort 4 CRC: minimum of 2 and maximum of 4 prior regimens, which must have
             included both an irinotecan and an oxaliplatin based regimen unless unable to tolerate
             irinotecan chemotherapy

        Laboratory:

          -  Adequate hematologic function:

               -  Absolute neutrophil count ≥1500 cells/mm3 (1.5 x 109/L)

               -  Platelet count >80,000 cells/mm3 (80 x 109/L) for cohort 1 (RCC)

               -  Platelet counts >100,000 cells/mm3 (100 x 109/L) for all UC cohorts

               -  Hemoglobin ≥8.0 g/dL. for cohort 1 (RCC),all UC cohorts, and cohort 3 (GC)

               -  Hemoglobin ≥9.0 g/dL for cohort 4 (CRC)

          -  Adequate hepatic and renal function defined as:

               -  Serum aspartate transaminase (AST) and/or alanine transaminase (ALT) ≤5.0 x upper

               -  limit of normal (ULN) if liver metastases, or ≤3 x ULN without liver metastases

               -  Alkaline phosphatase <3.0 x ULN or ≤5.0 x ULN if liver or bone metastases present

               -  Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of
                  non-hepatic

               -  origin, such as hemolysis) with the exception of subjects in the GC cohort where

               -  docetaxel is administered, these subjects must have bilirubin within normal
                  limits (WNL)

               -  Estimated Creatinine Clearance ≥30 mL/min (Cockcroft-Gault)

        Exclusion Criteria

          -  Prior treatment with:

               -  Everolimus or temsirolimus (RCC cohort 1)

               -  Any taxane (UC cohort of ibrutinib + paclitaxel) (cohort 2)

               -  Checkpoint inhibitors (UC cohort 6)

               -  Any taxane (GC cohort 3)

               -  Cetuximab or panitumumab (CRC cohort 4)

          -  For all Cohorts:

               -  Concomitant use of warfarin or other Vitamin K antagonists

               -  History of stroke or intracranial hemorrhage within 6 months prior to enrollment

               -  Major surgery within 4 weeks of first dose of study drug

               -  Requires treatment with strong CYP3A inhibitors known bleeding disorders or
                  hemophilia

          -  UC cohort 6 only:

               -  Subjects who have an active, known or suspected autoimmune disease.

               -  Evidence of clinically significant interstitial lung disease or active,
                  noninfectious pneumonitis.

               -  Non-steroid immunosuppressive medications within 14 days before the first dose of
                  ibrutinib and pembrolizumab.

               -  Subjects in whom prior anti PD-1 / anti-PD-L1 therapy was intolerable and
                  required discontinuation of treatment.